Galderma received FDA approval for Restylane Contour for correction of temple hollowing, a common age-related volume loss that drives patient consultations but has lacked a cleared filler indication. Temple augmentation has been performed off-label with various HA and biostimulator products, but the cleared pathway reduces documentation burden and strengthens the clinical foundation for treatment.
Restylane Contour's particle size and rheology (designed for structural support and lift) make it mechanically suited to temple placement, where the goal is restoring volume in a relatively fixed anatomic pocket. The indication sits naturally within Galderma's volumization portfolio alongside Restylane Lyft and Restylane Defyne, allowing practices to sequence products by depth and clinical objective.